Company Overview
BioHarvest Sciences Inc. operates as a biotechnology firm based in Israel and the United States, utilizing a botanical synthesis platform technology to produce plant cells with higher concentrations of active ingredients through its Nutraceuticals and Pharmaceuticals segments. The company functions within the Consumer Defensive sector and the Packaged Foods industry, positioning its products in markets where demand tends to remain stable regardless of economic fluctuations. With a market capitalization of $97.92M and annual revenue of $32.72M, the firm represents a small-cap entity within the broader biotechnology and packaged goods landscape. The employee count is not disclosed in available public records, indicating a lean operational structure typical for early-stage biotech firms. These financial figures suggest the company is a niche player that has achieved significant revenue expansion but has not yet scaled to the size of large-cap pharmaceutical peers, reflecting a high-risk, high-potential growth trajectory common in the sector.
Financial Health
The company reported total revenue of $32.72M over the trailing twelve months, yet it recorded a net income loss of $11,887,000 and an EBITDA of $-5,409,000. The substantial gap between positive revenue and negative net income reveals a cost structure where operating expenses, likely driven by research and development and commercialization efforts, significantly erode profitability before taxes. Free cash flow stands at $-6,726,250, indicating that the company is currently burning cash to fund operations and growth initiatives rather than generating surplus liquidity for debt reduction or shareholder returns. This negative cash flow suggests limited immediate financial flexibility, requiring continuous access to capital markets or existing cash reserves to sustain operations. Regarding profitability margins, the gross margin is 59.2%, which indicates a strong pricing power or high efficiency in the production phase; however, the operating margin of -10.1% and profit margin of -36.3% demonstrate that overhead costs and non-operating expenses are overwhelming gross profits. The company holds $10.97M in cash against $17.36M in debt, resulting in a debt-to-equity ratio of 224.46%, which signals a highly leveraged balance sheet where liabilities exceed equity by a wide margin. Liquidity is assessed via a current ratio of 1.35, suggesting the firm possesses enough current assets to cover short-term obligations, though the buffer is relatively thin given the negative operating cash flow. Return on equity is -200.2% and return on assets is -12.6%, metrics that reveal management has not yet achieved positive returns on the capital invested or deployed, highlighting the early-stage nature of the business model.
Valuation Assessment
Valuation metrics present a complex picture due to the company's current unprofitability, with a trailing P/E ratio listed as N/A and a forward P/E of -24.00. The negative forward P/E implies that analysts or market participants are pricing in the expectation that earnings will turn positive in the future, or that the stock is valued based on non-traditional metrics since current earnings are negative. The price-to-book ratio is 10.96, indicating that the market values the company at a significant premium over its net asset value, a common occurrence in biotechnology firms where intangible assets like intellectual property drive value rather than book assets. Alternative valuation measures include a price-to-sales ratio of 2.99 and an EV/EBITDA of -19.28, which suggest the market is willing to pay nearly three times annual sales for the company, reflecting high growth expectations despite current losses. The stock has traded between a 52-week high of $12.80 and a 52-week low of $4.10, creating a trading range of $8.70. Without a specific current price provided in the source data, the valuation must be interpreted relative to this historical volatility, where the stock has demonstrated the ability to fluctuate widely within this band. The beta is 1.41, meaning the stock is expected to be 41% more volatile than the broader market, amplifying both potential gains and losses during periods of market movement.
Growth & Income
Revenue growth year-over-year is 38.7%, while earnings growth is N/A due to the company's current lack of profitability. The disparity between robust revenue expansion and the inability to calculate earnings growth rates implies that the company is prioritizing market share capture and product development over immediate profit generation. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute cash to shareholders, instead retaining all earnings to reinvest into research, development, and commercialization activities. This reinvestment strategy is characteristic of biotechnology firms in the nutraceuticals and pharmaceuticals segments that require substantial capital expenditure to advance their botanical synthesis platform technology. The overall growth and income profile is defined by rapid revenue expansion coupled with significant cash burn and no current income distribution, positioning the company as a pure-play growth investment for investors seeking exposure to biotech innovation rather than current yield.